Soligenix announces FDA clearance of phase 3 clinical protocol of SGX301
Soligenix announced an agreement with the FDA on the design of a pivotal, Phase 3 clinical trial evaluating its product SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma. SGX301 is a novel, first-in-class, photodynamic therapy utilizing safe visible light for activation. September 17, 2014